Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”

A recent study reported that the high-dose quadrivalent influenza vaccine provided superior immunogenicity and efficacy versus the standard-dose quadrivalent vaccine in the elderly. However, we need to view these results in terms of public health benefits as well. The Number Needed to Vaccinate (NNV...

Descripción completa

Detalles Bibliográficos
Autores principales: Hadigal, Sanjay, Colombo, Laura, Haughie, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Influenza – Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624209/
https://www.ncbi.nlm.nih.gov/pubmed/35674507
http://dx.doi.org/10.1080/21645515.2022.2085470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624209/
https://www.ncbi.nlm.nih.gov/pubmed/35674507
http://dx.doi.org/10.1080/21645515.2022.2085470

Ejemplares similares